Shares of Tempest Therapeutics (TPST) ended higher on Wednesday amid a broader market rebound on the U.S. pausing tariffs and ...

Fintel reports that on April 10, 2025, Scotiabank downgraded their outlook for Tempest Therapeutics (NasdaqCM:TPST) from ...

Amid a funding drought for startups, the company is looking for a deal that can advance its liver cancer drug.

Amezalpat (TPST-1120) is Phase 3-ready: completed FDA and EMA interactions for first-line pivotal study in hepatocellular ...

Tempest Therapeutics hires MTS Health to explore M&A and partnerships after Roche shows limited interest in its liver cancer ...

According to Tempest, its options include a partnership or licensing deal, as well as a merger or an acquisition.

Unable to secure additional financing amid a stormy market, Tempest Therapeutics has put a call out for partners as it seeks ...

Tempest Therapeutics (TPST) announced that the company plans to explore a full range of strategic alternatives to advance its clinical stage ...

Scotiabank analyst George Farmer downgraded Tempest Therapeutics (TPST) to Sector Perform from Outperform with a reverse stock-split adjusted ...

California-based clinical-stage biotech Tempest Therapeutics (Nasdaq: TPST) has announced that the company plans to explore a ...

HC Wainwright reaffirmed their neutral rating on shares of Tempest Therapeutics (NASDAQ:TPST – Free Report) in a report published on Thursday morning, Marketbeat reports. They currently have a $ ...

Tempest Therapeutics is exploring strategic alternatives for the business, including mergers, partnerships, acquisition, joint ventures and licensing agreements. Shares rose 9.2% to $7.81 in ...